Prostate Cancer

Findings suggest many patients with localized disease can delay surgery or radiation without increasing their mortality risk.

“As the ability to target improved, what we really clearly saw was the idea that perhaps a treatment course could be shortened significantly, and that the term hypofractionation became commonly applied to men with prostate cancer,” said Walter J. Curran Jr, MD, FACR, FASCO.

“What is precision medicine? This is not just a vague term; it really looks at individual characteristics of a patient to decide treatment," said Leonard G. Gomella, MD, FACS.

"The government is spending more in Medicare, we are getting more people with prostate cancer, more deaths with prostate cancer, [and] more metastasis with prostate cancer. While it is so simple: today, PSA is still there," says Navin Shah, MD, MS, FACS, FICS, FACIP.

"While past global studies have supported the use of Xtandi plus ADT in men with mHSPC, it is encouraging to see these results replicated for patients in mainland China," said Zhou Fangjian, MD.

"We think this is an important call to action for the NCCN to follow in the footsteps of the AUA, who recently removed VLR from its prostate cancer guidelines in its most recent update," says Kevin Shee, MD, PhD.

"Our recommendation is to adopt a Mediterranean diet enlisting the help of a dietician, because people absorb nutrients in different ways, depending on the food, the digestive system, the person’s genotype and possibly their microbiome," says Permal Deo, MD.

"Our hope is that this study, and others, will encourage a review of the levels of nitrate that are allowed in water, in order to ensure that there is no risk to human health,” said Carolina Donat-Vargas, PhD, MPH.

"The pendulum is swinging back. It’s all about provider education, hammering home the point that we have to do appropriate screening," says urologist Ryan Hankins, MD.

"AI has...been increasingly utilized in the field of medicine, including cancer research, because of its potential to improve diagnostic accuracy, prognosis prediction, and personalized treatment planning," writes Michael S. Cookson, MD, MMHC.

"[Although] American Indian/Alaskan Native patients do present with more advanced prostate cancer, show lower rates of definitive treatment, and higher mortality, once we adjust for some of these disparities in access, we found that there were no significant differences in mortality," says Carissa E. Chu, MD.

“Metastatic castration-resistant prostate cancer remains a lethal disease, with high unmet needs in terms of treatment options, particularly for patients with BRCA1/2 gene mutations,” said Elena, MD, PhD

The application is supported by findings from the phase 3 MAGNITUDE study.

Immunotherapy utilization and costs accounted for 84% of the net increase in Medicare Part B payments, yet the treatment was administered to fewer than 20% of patients.

The addition of pembrolizumab to enzalutamide and ADT did not extend survival or delay disease progression compared with enzalutamide and ADT alone.

Medical oncologist Joelle Hamilton, MD, reflects on the prevalence of cardiovascular risk while managing prostate cancer in patients.

Direct insight from a cardiologist on the advent of cardiovascular risk when treating a patient for prostate cancer.

Cleveland Clinic highlights its use of irreversible electroporation, also known as Nanoknife, in select patients with prostate cancer.

Yale School of Medicine Associate Professor of Urology Michael Leapman, MD, MHS, and coauthors estimated the environmental impacts of prostate MRI and prostate biopsy.

"We found a sizeable and statistically significant uptick in compliance with genetic testing and compliance with post-test genetic counseling in patients who underwent testing after the implementation of the standardized protocol," says Siddharth Ramanathan.

"It will only be when the indications for focal therapy are expanded to higher-grade and larger tumors that we will begin to learn about the true efficacy of this approach," writes Badar M. Mian, MD.

Treatment with rucaparib reduced risk of imaging-based progression or death by half in men with BRCA-altered metastatic castration-resistant prostate cancer.

The combination use of niraparib plus abiraterone and prednisone continued to improve outcomes in patients with metastatic, castration-resistant prostate cancer and HRR gene alterations.

Expert perspectives on strategies to optimize communication, both between healthcare professionals and with patients who present with prostate cancer.

Cardiologist Anees A. Daud, MD, breaks down the typical patient with prostate cancer seen at his practice.

Urologist David Morris, MD, FACS, defines the typical patient with prostate cancer treated at his practice.

Oncologist Joelle Hamilton, MD, shares her perspective on the typical patient with prostate cancer seen at her institution.

Centering focus on a patient case of cardiovascular risk and prostate cancer, experts share their perspective on management strategies.

Comprehensive insight regarding strategies to mitigate cardiovascular risk in patients on therapy for prostate cancer.

Shared insight on a timeline of clinical studies contextualizing cardiovascular disease in the setting of prostate cancer management.